EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subjective and objective olfactory dysfunction and its screening value in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s dementia

Philipp Dopke, Johann Lehrner

neuropsychiatrie · 05.06.2026

DOI: 10.1007/s40211-026-00581-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift neuropsychiatrie, online erschienen am 05.06.2026. Verfasst von Philipp Dopke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to an ageing population and increased life expectancy, Alzheimer’s dementia (AD) is becoming increasingly important. Since AD is characteristically preceded by subjective cognitive decline (SCD) and mild cognitive impairment (MCI), innovative diagnostic tools and therapeutics are essential for diagnosis at an early stage. Olfactory dysfunction is commonly associated with cognitive decline, indicating its potential as a diagnostic marker.

Objective

This study examined the association between olfactory function, evaluated with the Sniffin’ Sticks Odor Identification Test (SS-OIT), and Assessment of Self-Reported Olfactory Functioning (ASOF) inventory across five cognitive subgroups (healthy controls [HC], SCD, non-amnestic MCI, amnestic MCI, and AD). Furthermore, this study investigated the utility of olfactory testing in screening for AD.

Methods

This retrospective, single-center cross-sectional study was conducted at the Neurology Department of the Medical University of Vienna. The study included 958 participants during the period 2000–2023. Cognitive and olfactory functions were assessed using standardized neuropsychological and olfactory tools. Statistical analyses included descriptive measures, analysis of variance (ANOVA), model testing, and the receiver operating characteristic (ROC) methodology.

Results

Olfactory performance declined with increasing cognitive impairment, with the strongest contrast showing an effect size of r = 0.51 between HC and AD. The SS-OIT (area under the ROC curve [AUC]: 75.3%) and Olfactory-Related Quality of Life subscale (ORQ; AUC: 64.8%) were identified as the most effective in distinguishing AD, with the following recommended cut-offs: SS-OIT ≤ 9; Subjective Olfactory Capability (SOC) ≤ 6; Self-Reported Capability of Perceiving Specific Odors (SRP) ≤ 4.10; and ORQ ≤ 3.67.

Conclusion

Olfactory functioning shows moderate reliability in distinguishing subgroups; nevertheless, the proposed cut-off values may be suitable for AD screening. Further studies are recommended to confirm our findings.

Schlagwörter

Stichwörter der Autor:innen

ASOFAlzheimer’s dementiaCognitive declineOlfactory assessmentSniffin’ Sticks

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. johann.lehrner@meduniwien.ac.at.

Förderung

  • Medical University of Vienna

Zitieren

APA

Dopke, P., & Lehrner, J. (2026). Subjective and objective olfactory dysfunction and its screening value in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s dementia. neuropsychiatrie. https://doi.org/10.1007/s40211-026-00581-7

Vancouver

Dopke P, Lehrner J. Subjective and objective olfactory dysfunction and its screening value in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s dementia. neuropsychiatrie. 2026. doi:10.1007/s40211-026-00581-7

BibTeX
@article{Dopke2026,
  author = {Dopke, Philipp and Lehrner, Johann},
  title = {Subjective and objective olfactory dysfunction and its screening value in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s dementia},
  journal = {neuropsychiatrie},
  year = {2026},
  doi = {10.1007/s40211-026-00581-7}
}
Kostenlos starten →